Amee M. Bigelow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amee M. Bigelow has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
John M. Clark
Department of Cardiology, The Heart Center, Akron Children's Hospital, Akron, OH, USA
3 shared publicationsPeter White
3 shared publicationsAdam M. Lubert
Department of Pediatrics, The Heart Institute, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, USA
2 shared publicationsAndrew T. Trout
Department of Radiology, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, USA
2 shared publicationsAngela C. Onorato
2 shared publicationsAva Willoughby
2 shared publications
Latest Publications
- Open Access
- 1 February 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (2) , 44
Diagnostic yield of exome and genome sequencing for critically ill pediatric cardiac patients
Genetic testing guidelines for children in cardiac intensive care units (CICUs) remain limited despite a high prevalence of genetic diseases among this population. Advances in next-generation sequencing technologies, especially exome sequencing (ES) and genome sequencing (GS), enable more comprehensive genetic evaluations than traditional testing modalities such as chromosomal microarray (CMA). While testing recommendations exist for cardiomyopathies and arrhythmias, broad application of next-generation sequencing, especially ES/GS, across indications for admission to CICU has not been recommended amongst cardiology societies. We aimed to evaluate the diagnostic efficacy of ES/GS in critically ill pediatric patients with cardiac disease. Retrospective chart review of patients who underwent clinical ES/GS in a quaternary hospital’s pediatric CICU between January 2020 and August 2023. Patient demographics and clinical characteristics were collected and analyzed. Results were compared by test type, cardiac phenotype, and extracardiac anomalies status. Forty-five patients underwent clinical ES/GS, with median age at testing of 33 [7–905] days. Primary cardiac phenotypes included congenital heart disease (CHD), ventricular dysfunction, and arrhythmia. Diagnostic results were found in 20 patients (44.4%) with 18/20 (90%) linked to cardiac phenotypes. Diagnostic yield was not different among cardiac phenotype groups but was higher in patients with extracardiac anomalies. Notably, gene panels would have failed to make 36% of diagnoses made by ES/GS. ES and GS provided high diagnostic yield in critically ill cardiac patients across various phenotypes. As next-generation sequencing technologies and interpretation capabilities mature, diagnostic abilities in pediatric cardiac disease will continue to advance.
- 1 February 2026
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (2) , 44
Open AccessDiagnostic yield of exome and genome sequencing for critically ill pediatric cardiac patients
Genetic testing guidelines for children in cardiac intensive care units (CICUs) remain limited despite a high prevalence of genetic diseases among this population. Advances in next-generation sequencing technologies, especially exome sequencing (ES) and genome sequencing (GS), enable more comprehensive genetic evaluations than traditional testing modalities such as chromosomal microarray (CMA). While testing recommendations exist for cardiomyopathies and arrhythmias, broad application of next-generation sequencing, especially ES/GS, across indications for admission to CICU has not been recommended amongst cardiology societies. We aimed to evaluate the diagnostic efficacy of ES/GS in critically ill pediatric patients with cardiac disease. Retrospective chart review of patients who underwent clinical ES/GS in a quaternary hospital’s pediatric CICU between January 2020 and August 2023. Patient demographics and clinical characteristics were collected and analyzed. Results were compared by test type, cardiac phenotype, and extracardiac anomalies status. Forty-five patients underwent clinical ES/GS, with median age at testing of 33 [7–905] days. Primary cardiac phenotypes included congenital heart disease (CHD), ventricular dysfunction, and arrhythmia. Diagnostic results were found in 20 patients (44.4%) with 18/20 (90%) linked to cardiac phenotypes. Diagnostic yield was not different among cardiac phenotype groups but was higher in patients with extracardiac anomalies. Notably, gene panels would have failed to make 36% of diagnoses made by ES/GS. ES and GS provided high diagnostic yield in critically ill cardiac patients across various phenotypes. As next-generation sequencing technologies and interpretation capabilities mature, diagnostic abilities in pediatric cardiac disease will continue to advance.
- 20 November 2025
- Published by Springer Nature in Pediatric Cardiology
- Vol. 47 (7) , 3005-3013
Genetic Evaluation Practices for Neonates with Congenital Heart Disease in Pediatric Cardiac Intensive Care Units: Findings from a Multi-institutional Survey
Genetic testing plays an expanding role in pediatric cardiology, particularly in congenital heart disease (CHD). Despite advancements in genomic medicine, no universal guidelines exist for genetic evaluation in CHD, resulting in varied practices, especially within Cardiac Intensive Care Units (CICUs). This study examines genetic evaluation practices for neonates with CHD cared for in pediatric CICUs across the United States. A two-tier survey of CICU medical directors and genetic specialists was distributed via RedCap to 118 centers contributing to the Society of Thoracic Surgeons Congenital Heart Surgery Database. Surveys assessed CICU demographics, genetic evaluation practices, and institutional protocols. Descriptive statistics were analyzed using R. Fifty unique institutions (42%) completed the first-tier survey; 46/50 completed the second-tier. Most (78%) respondents reported dedicated CICUs, but only 32% had formal genetic testing protocols. Tier 1 showed genetic testing was reported in 58% of neonatal CHD cases, the remainder evaluated on a case-by-case basis. Substantial variability existed in both cardiac substrates prompting genetic evaluation and first-line test selection. Only 28% reported consultation with genetic providers for neonatal CHD cases. Tier 2 showed genetic consultation increased to 54% for patients with syndromic CHD, and genetic testing was obtained in 46% of isolated and 61% of syndromic CHD. Access remained limited as only 42% had cardiac-specific genetic providers. Fewer than 12% of institutions used exome or genome as first-line testing. Genetic evaluation in CICUs is highly variable, with underutilization of genetic providers and limited access to advanced testing. Standardized guidelines and consensus statements are needed to improve access, streamline care, optimize outcomes, and enable genome-informed management in CHD.
- 20 November 2025
- Published by Springer Nature in Pediatric Cardiology
- Vol. 47 (7) , 3005-3013
Genetic Evaluation Practices for Neonates with Congenital Heart Disease in Pediatric Cardiac Intensive Care Units: Findings from a Multi-institutional Survey
Genetic testing plays an expanding role in pediatric cardiology, particularly in congenital heart disease (CHD). Despite advancements in genomic medicine, no universal guidelines exist for genetic evaluation in CHD, resulting in varied practices, especially within Cardiac Intensive Care Units (CICUs). This study examines genetic evaluation practices for neonates with CHD cared for in pediatric CICUs across the United States. A two-tier survey of CICU medical directors and genetic specialists was distributed via RedCap to 118 centers contributing to the Society of Thoracic Surgeons Congenital Heart Surgery Database. Surveys assessed CICU demographics, genetic evaluation practices, and institutional protocols. Descriptive statistics were analyzed using R. Fifty unique institutions (42%) completed the first-tier survey; 46/50 completed the second-tier. Most (78%) respondents reported dedicated CICUs, but only 32% had formal genetic testing protocols. Tier 1 showed genetic testing was reported in 58% of neonatal CHD cases, the remainder evaluated on a case-by-case basis. Substantial variability existed in both cardiac substrates prompting genetic evaluation and first-line test selection. Only 28% reported consultation with genetic providers for neonatal CHD cases. Tier 2 showed genetic consultation increased to 54% for patients with syndromic CHD, and genetic testing was obtained in 46% of isolated and 61% of syndromic CHD. Access remained limited as only 42% had cardiac-specific genetic providers. Fewer than 12% of institutions used exome or genome as first-line testing. Genetic evaluation in CICUs is highly variable, with underutilization of genetic providers and limited access to advanced testing. Standardized guidelines and consensus statements are needed to improve access, streamline care, optimize outcomes, and enable genome-informed management in CHD.
- Open Access
- 6 May 2025
- Published by Springer Nature in Research Square
Evaluation of Exome and Genome Sequencing for Critically Ill Pediatric Cardiac Patients
Genetic testing guidelines for children in cardiac intensive care units (CICUs) are lacking despite a high prevalence of genetic diseases among this population. Advances in next-generation sequencing (NGS) technologies, especially exome and genome sequencing (ES/GS), enable a more comprehensive genetic evaluation than more traditional testing modalities such as chromosomal microarray (CMA). While testing recommendations exist for cardiomyopathies, primary arrhythmias, and pulmonary hypertension (PH), broad application of NGS, especially ES/GS, across indications for admission to CICUs has not been recommended. We aimed to evaluate the diagnostic efficacy of ES/GS in critically ill pediatric patients with cardiac disease via a retrospective chart review of patients who underwent clinical ES/GS in a quaternary hospital’s pediatric CICU between January 2020 and August 2023. Forty-nine patients underwent ES/GS. Primary cardiac phenotypes included congenital heart disease, ventricular dysfunction, arrhythmia, and PH. Diagnostic results were found in 22 patients (44.9%) with 18/22 (81.8%) linked to cardiac phenotypes. Diagnostic yield was not different among primary cardiac phenotype groups but was higher in patients with ECA. CMA and gene panels would have failed to make a substantial proportion (80.6% and 36%, respectively) of diagnoses made by ES/GS. As NGS technologies and capabilities to interpret ES/GS data mature, diagnostic abilities in pediatric cardiac disease will continue to advance.
- 6 May 2025
- Published by Springer Nature in Research Square
Open AccessEvaluation of Exome and Genome Sequencing for Critically Ill Pediatric Cardiac Patients
Genetic testing guidelines for children in cardiac intensive care units (CICUs) are lacking despite a high prevalence of genetic diseases among this population. Advances in next-generation sequencing (NGS) technologies, especially exome and genome sequencing (ES/GS), enable a more comprehensive genetic evaluation than more traditional testing modalities such as chromosomal microarray (CMA). While testing recommendations exist for cardiomyopathies, primary arrhythmias, and pulmonary hypertension (PH), broad application of NGS, especially ES/GS, across indications for admission to CICUs has not been recommended. We aimed to evaluate the diagnostic efficacy of ES/GS in critically ill pediatric patients with cardiac disease via a retrospective chart review of patients who underwent clinical ES/GS in a quaternary hospital’s pediatric CICU between January 2020 and August 2023. Forty-nine patients underwent ES/GS. Primary cardiac phenotypes included congenital heart disease, ventricular dysfunction, arrhythmia, and PH. Diagnostic results were found in 22 patients (44.9%) with 18/22 (81.8%) linked to cardiac phenotypes. Diagnostic yield was not different among primary cardiac phenotype groups but was higher in patients with ECA. CMA and gene panels would have failed to make a substantial proportion (80.6% and 36%, respectively) of diagnoses made by ES/GS. As NGS technologies and capabilities to interpret ES/GS data mature, diagnostic abilities in pediatric cardiac disease will continue to advance.
- Open Access
- 27 December 2023
- Published by Elsevier in Annals of Thoracic Surgery Short Reports
- Vol. 2 (2) , 277-281
Rescuing the Right Ventricle: Mechanical Support After Pediatric Heart Transplantation
- 27 December 2023
- Published by Elsevier in Annals of Thoracic Surgery Short Reports
- Vol. 2 (2) , 277-281
Open AccessRescuing the Right Ventricle: Mechanical Support After Pediatric Heart Transplantation
- 1 August 2023
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 116 (5) , 995-996
Shades of uncertainty: Perspectives on Hypoplastic Left Heart Syndrome in premature and low birth weight infants
- 1 August 2023
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 116 (5) , 995-996
Shades of uncertainty: Perspectives on Hypoplastic Left Heart Syndrome in premature and low birth weight infants
- Open Access
- 28 June 2023
- Published by EDP Sciences in The Journal of ExtraCorporeal Technology
- Vol. 55 (2) , 60-69
A ROTEM-guided algorithm aimed to reduce blood product utilization during neonatal and infant cardiac surgery
Background: Neonates and infants undergoing cardiac surgery tend to receive high volumes of blood products. The use of rotational thromboelastometry (ROTEM®) has been shown to reduce the administration of blood products in adults after cardiac surgery. We sought to develop a targeted administration of blood products based on ROTEM®to reduce blood product utilization during and after neonatal and infant cardiac surgery.Methods: We conducted a retrospective review of data from a single center for neonates and infants undergoing congenital cardiac surgery using cardiopulmonary bypass (CPB) from September 2018-April 2019 (control group). Then, using a ROTEM®algorithm, we collected data prospectively between April-November 2021 (ROTEM group). Data collected included age, weight, gender, procedure, STAT score, CPB time, aortic cross-clamp time, volume, and type of blood products administered in the operating room and cardiothoracic intensive care unit (CTICU). In addition, ROTEM®data, coagulation profile in CTICU, chest tube output at 6 and 24 hours, use of factors concentrate, and thromboembolic complications were recorded.Results: The final cohort of patients included 28 patients in the control group and 40 patients in the ROTEM group. The cohort included neonates and infants undergoing the following procedures: arterial switch, aortic arch augmentation, Norwood procedure, and comprehensive stage II procedure. There were no differences in the demographics or procedure complexity between the two groups. Patients in the ROTEM®group received fewer platelets (36 ± 12 vs. 49 ± 27 mL/kg, p 0.028) and cryoprecipitate (8 ± 3 vs. 15 ± 10 mL/kg, p 0.001) intraoperatively when compared to the control group.Conclusion: The utilization of ROTEM®may have contributed to a significant reduction in some blood product administration during cardiac surgery for infants and neonates. ROTEM®data may play a role in reducing blood product administration in neonatal and infant cardiac surgery.
- 28 June 2023
- Published by EDP Sciences in The Journal of ExtraCorporeal Technology
- Vol. 55 (2) , 60-69
Open AccessA ROTEM-guided algorithm aimed to reduce blood product utilization during neonatal and infant cardiac surgery
Background: Neonates and infants undergoing cardiac surgery tend to receive high volumes of blood products. The use of rotational thromboelastometry (ROTEM®) has been shown to reduce the administration of blood products in adults after cardiac surgery. We sought to develop a targeted administration of blood products based on ROTEM®to reduce blood product utilization during and after neonatal and infant cardiac surgery.Methods: We conducted a retrospective review of data from a single center for neonates and infants undergoing congenital cardiac surgery using cardiopulmonary bypass (CPB) from September 2018-April 2019 (control group). Then, using a ROTEM®algorithm, we collected data prospectively between April-November 2021 (ROTEM group). Data collected included age, weight, gender, procedure, STAT score, CPB time, aortic cross-clamp time, volume, and type of blood products administered in the operating room and cardiothoracic intensive care unit (CTICU). In addition, ROTEM®data, coagulation profile in CTICU, chest tube output at 6 and 24 hours, use of factors concentrate, and thromboembolic complications were recorded.Results: The final cohort of patients included 28 patients in the control group and 40 patients in the ROTEM group. The cohort included neonates and infants undergoing the following procedures: arterial switch, aortic arch augmentation, Norwood procedure, and comprehensive stage II procedure. There were no differences in the demographics or procedure complexity between the two groups. Patients in the ROTEM®group received fewer platelets (36 ± 12 vs. 49 ± 27 mL/kg, p 0.028) and cryoprecipitate (8 ± 3 vs. 15 ± 10 mL/kg, p 0.001) intraoperatively when compared to the control group.Conclusion: The utilization of ROTEM®may have contributed to a significant reduction in some blood product administration during cardiac surgery for infants and neonates. ROTEM®data may play a role in reducing blood product administration in neonatal and infant cardiac surgery.
- 21 April 2023
- Published by Springer Nature in Pediatric Cardiology
- Vol. 45 (7) , 1389-1397
Isosorbide DiNitrate Effect on Hemodynamic Profile, Liver Stiffness, and Exercise Tolerance in Fontan Circulation (The NEET Clinical Trial)
After Fontan operation, decreased venous capacitance and venoconstriction are adaptive mechanisms to maintain venous return and cardiac output. The consequent higher venous pressure may adversely impact end-organ function, exercise capacity and result in worse clinical outcomes. This pilot study evaluated the safety and effect of isosorbide dinitrate (ISDN), a venodilator, on exercise capacity, peripheral venous pressure (PVP), and liver stiffness in patients with Fontan circulation. In this prospective single-arm trial, 15 individuals with Fontan circulation were evaluated at baseline and after 4 weeks of therapeutic treatment with ISDN. Primary aims were to assess the safety of ISDN and the effect on maximal exercise. We also aimed to evaluate the effect of ISDN on ultrasound-assessed liver stiffness, markers of submaximal exercise, and PVP at rest and peak exercise. Repeated measures t-tests were used to assess change in variables of interest in response to ISDN. Mean age was 23.5 ± 9.2 years (range 11.2–39.0 years), and 10/15 (67%) were male. There was no statistically significant change in peak VO2 (1401 ± 428 to 1428 ± 436 mL/min, p = 0.128), but VO2 at the anaerobic threshold increased (1087 ± 313 to 1115 ± 302 mL/min, p = 0.03). ISDN was also associated with a lower peak exercise PVP (22.5 ± 4.5 to 20.6 ± 3.0 mmHg, p = 0.015). Liver stiffness was lower with ISDN, though the difference was not statistically significant (2.3 ± 0.4 to 2.1 ± 0.5 m/s, p = 0.079). Of the patients completing the trial, mild headache was common (67%), but there were no major adverse events. Treatment with ISDN for 4 weeks is well-tolerated in patients with a Fontan circulation. ISDN is associated with an increase in VO2 at anaerobic threshold, lower peak PVP, and a trend toward lower liver stiffness. Larger, longer duration studies will be necessary to define the impact of ISDN on clinical outcomes in the Fontan circulation. Clinical Trial Registration: URL: https://clinicaltrials.gov. Unique identifier: NCT04297241.
- 21 April 2023
- Published by Springer Nature in Pediatric Cardiology
- Vol. 45 (7) , 1389-1397
Isosorbide DiNitrate Effect on Hemodynamic Profile, Liver Stiffness, and Exercise Tolerance in Fontan Circulation (The NEET Clinical Trial)
After Fontan operation, decreased venous capacitance and venoconstriction are adaptive mechanisms to maintain venous return and cardiac output. The consequent higher venous pressure may adversely impact end-organ function, exercise capacity and result in worse clinical outcomes. This pilot study evaluated the safety and effect of isosorbide dinitrate (ISDN), a venodilator, on exercise capacity, peripheral venous pressure (PVP), and liver stiffness in patients with Fontan circulation. In this prospective single-arm trial, 15 individuals with Fontan circulation were evaluated at baseline and after 4 weeks of therapeutic treatment with ISDN. Primary aims were to assess the safety of ISDN and the effect on maximal exercise. We also aimed to evaluate the effect of ISDN on ultrasound-assessed liver stiffness, markers of submaximal exercise, and PVP at rest and peak exercise. Repeated measures t-tests were used to assess change in variables of interest in response to ISDN. Mean age was 23.5 ± 9.2 years (range 11.2–39.0 years), and 10/15 (67%) were male. There was no statistically significant change in peak VO2 (1401 ± 428 to 1428 ± 436 mL/min, p = 0.128), but VO2 at the anaerobic threshold increased (1087 ± 313 to 1115 ± 302 mL/min, p = 0.03). ISDN was also associated with a lower peak exercise PVP (22.5 ± 4.5 to 20.6 ± 3.0 mmHg, p = 0.015). Liver stiffness was lower with ISDN, though the difference was not statistically significant (2.3 ± 0.4 to 2.1 ± 0.5 m/s, p = 0.079). Of the patients completing the trial, mild headache was common (67%), but there were no major adverse events. Treatment with ISDN for 4 weeks is well-tolerated in patients with a Fontan circulation. ISDN is associated with an increase in VO2 at anaerobic threshold, lower peak PVP, and a trend toward lower liver stiffness. Larger, longer duration studies will be necessary to define the impact of ISDN on clinical outcomes in the Fontan circulation. Clinical Trial Registration: URL: https://clinicaltrials.gov. Unique identifier: NCT04297241.
- Open Access
- 9 January 2023
- Published by Springer Nature in Research Square
Isosorbide DiNitrate Effect on Hemodynamic Profile, Liver Stiffness, and Exercise Tolerance in Fontan Circulation (The NEET Clinical Trial)
Introduction: After Fontan operation, decreased venous capacitance and venoconstriction are adaptive mechanisms to maintain venous return and cardiac output. The consequent higher venous pressure may adversely impact end-organ function, exercise capacity and result in worse clinical outcomes. This pilot study evaluated the safety and effect of isosorbide dinitrate (ISDN), a venodilator, on exercise capacity, peripheral venous pressure (PVP), and liver stiffness in patients with Fontan circulation. Methods: In this prospective single-arm trial, 15 individuals with Fontan circulation were evaluated at baseline and after four weeks of therapeutic treatment with ISDN. Primary aims were to assess the safety of ISDN and the effect on maximal exercise (peak oxygen consumption, peak VO2). We also aimed to assess the effect of ISDN on ultrasound-assessed liver stiffness, markers of submaximal exercise, and PVP at rest and peak exercise. Repeated measures t-tests were used to assess change in variables of interest in response to ISDN. Results: Mean age was 23.5 ± 9.2 years (range 11.2-39.0 years), and 10/15 (67%) were male. There was no statistically significant change in peak VO2 (1401±428 to 1428±436 mL/min, p=0.128), but VO2 at the anaerobic threshold increased (1087 + 313 to 1115 + 302 mL/min, p= 0.03). ISDN was also associated with a lower peak exercise PVP (22.5 + 4.5 to 20.6 + 3.0 mmHg, p=0.015). Liver stiffness was lower with ISDN, though the difference was not statistically significant (2.3 + 0.4 to 2.1 + 0.5 m/s, p=0.079). Of the patients completing the trial, mild headache was common (67%), but there were no major adverse events. Conclusions: Treatment with ISDN for 4 weeks is well-tolerated in patients with a Fontan circulation. ISDN is associated with an increase in VO2 at anaerobic threshold, lower peak PVP, and a trend towards lower liver stiffness. Larger, longer studies will be necessary to define the impact of ISDN on clinical outcomes in the Fontan circulation. Clinical Trial Registration: URL: https//clinicaltrials.gov. Unique identifier: NCT04297241
- 9 January 2023
- Published by Springer Nature in Research Square
Open AccessIsosorbide DiNitrate Effect on Hemodynamic Profile, Liver Stiffness, and Exercise Tolerance in Fontan Circulation (The NEET Clinical Trial)
Introduction: After Fontan operation, decreased venous capacitance and venoconstriction are adaptive mechanisms to maintain venous return and cardiac output. The consequent higher venous pressure may adversely impact end-organ function, exercise capacity and result in worse clinical outcomes. This pilot study evaluated the safety and effect of isosorbide dinitrate (ISDN), a venodilator, on exercise capacity, peripheral venous pressure (PVP), and liver stiffness in patients with Fontan circulation. Methods: In this prospective single-arm trial, 15 individuals with Fontan circulation were evaluated at baseline and after four weeks of therapeutic treatment with ISDN. Primary aims were to assess the safety of ISDN and the effect on maximal exercise (peak oxygen consumption, peak VO2). We also aimed to assess the effect of ISDN on ultrasound-assessed liver stiffness, markers of submaximal exercise, and PVP at rest and peak exercise. Repeated measures t-tests were used to assess change in variables of interest in response to ISDN. Results: Mean age was 23.5 ± 9.2 years (range 11.2-39.0 years), and 10/15 (67%) were male. There was no statistically significant change in peak VO2 (1401±428 to 1428±436 mL/min, p=0.128), but VO2 at the anaerobic threshold increased (1087 + 313 to 1115 + 302 mL/min, p= 0.03). ISDN was also associated with a lower peak exercise PVP (22.5 + 4.5 to 20.6 + 3.0 mmHg, p=0.015). Liver stiffness was lower with ISDN, though the difference was not statistically significant (2.3 + 0.4 to 2.1 + 0.5 m/s, p=0.079). Of the patients completing the trial, mild headache was common (67%), but there were no major adverse events. Conclusions: Treatment with ISDN for 4 weeks is well-tolerated in patients with a Fontan circulation. ISDN is associated with an increase in VO2 at anaerobic threshold, lower peak PVP, and a trend towards lower liver stiffness. Larger, longer studies will be necessary to define the impact of ISDN on clinical outcomes in the Fontan circulation. Clinical Trial Registration: URL: https//clinicaltrials.gov. Unique identifier: NCT04297241
- 21 March 2022
- Published by Springer Nature in Pediatric Cardiology
- Vol. 43 (4) , 926-929
Management of Hypertrophic Cardiomyopathy in a Newborn with Dextro-Transposition of the Great Arteries
Impaired maternal glucose metabolism during pregnancy can have significant effects on the cardiovascular system of the developing fetus. Early in pregnancy the teratogenic effects may lead to structural heart defects, while later in gestation a form of hypertrophic cardiomyopathy can develop due to overgrowth driven by fetal hyperinsulinism. We describe an infant with the uncommon combination of both dextro-transposition of the great arteries and hypertrophic cardiomyopathy. We emphasize the importance of a longitudinal multi-disciplinary approach, from fetal diagnosis to post-operative management, that allowed for an excellent outcome in this rare combination of severe cardiac malformations.
- 21 March 2022
- Published by Springer Nature in Pediatric Cardiology
- Vol. 43 (4) , 926-929
Management of Hypertrophic Cardiomyopathy in a Newborn with Dextro-Transposition of the Great Arteries
Impaired maternal glucose metabolism during pregnancy can have significant effects on the cardiovascular system of the developing fetus. Early in pregnancy the teratogenic effects may lead to structural heart defects, while later in gestation a form of hypertrophic cardiomyopathy can develop due to overgrowth driven by fetal hyperinsulinism. We describe an infant with the uncommon combination of both dextro-transposition of the great arteries and hypertrophic cardiomyopathy. We emphasize the importance of a longitudinal multi-disciplinary approach, from fetal diagnosis to post-operative management, that allowed for an excellent outcome in this rare combination of severe cardiac malformations.